Cargando…
Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?
Human schistosomiasis is a disease which globally affects over 229 million people. Three major species affecting humans are Schistosoma mansoni, S. haematobium and S. japonicum. Previous treatment of S. mansoni includes the use of oxamniquine (OXA), a prodrug that is enzymatically activated in S. ma...
Autores principales: | Rugel, Anastasia R., Guzman, Meghan A., Taylor, Alexander B., Chevalier, Frédéric D., Tarpley, Reid S., McHardy, Stanton F., Cao, Xiaohang, Holloway, Stephen P., Anderson, Timothy J.C., Hart, P. John, LoVerde, Philip T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167500/ https://www.ncbi.nlm.nih.gov/pubmed/32315953 http://dx.doi.org/10.1016/j.ijpddr.2020.04.001 |
Ejemplares similares
-
An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans
por: Guzman, Meghan A., et al.
Publicado: (2020) -
Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deployment
por: Chevalier, Frédéric D., et al.
Publicado: (2019) -
Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis
por: Alwan, Sevan N., et al.
Publicado: (2023) -
Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments
por: Toth, Katalin, et al.
Publicado: (2023) -
Structural and Functional Characterization of the Enantiomers of the Antischistosomal Drug Oxamniquine
por: Taylor, Alexander B., et al.
Publicado: (2015)